Maplirpacept

Verified

Overview

Maplirpacept is a type of protein called a fusion protein, which is similar to an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells, and is used by cancer cells to hide from your body’s immune system.

SparkCures ID 344
Developed By Trillium Therapeutics, Inc, a Pfizer company
Generic Name Maplirpacept
Additional Names TTI-622
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Partic...
TTI-622
View Trial
Verified
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Trillium Therapeutics, Inc, a Pfizer company to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners